The weight loss pens, which have seen sales at Pague Menos more than double compared to traditional medications, accounted for 9.1% of the drugstore's sales between October and December, totaling R$ 4.3 billion. In stark contrast, medications covered under Brazil's Farmácia Popular program made up only 4.4% of the sales. The CEO of Pague Menos, Jonas Marques, boldly stated that these weight loss pens could be more revolutionary to society than the discovery of penicillin in 1928, due to their powerful effect on the limbic system which reportedly helps curb compulsive eating.

Jonas Marques, who has a background in psychology and 30 years of experience in the pharmaceutical industry, attributes the significant impact of weight loss pens to their active ingredient, GLP-1. This compound not only aids in weight loss but also addresses behavioral aspects of eating disorders, making it a potentially groundbreaking product for public health. Marques emphasizes that the psychological implications of this treatment could transform how society approaches obesity and weight management.

The Farmácia Popular program traditionally provides access to medications for chronic diseases and essential hygiene items, further highlighting the striking difference in market performance between conventional pharmaceuticals and innovative weight loss solutions. As consumer preferences shift towards these new treatments, the implications for public health policy and the pharmaceutical market in Brazil could be profound, ushering in a new era of treatment for obesity-related issues alongside traditional healthcare options.